Dr. Mekhail is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2501 N Orange Ave
Ste 689
Orlando, FL 32804Phone+1 407-265-6627
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1999 - 2002- Cleveland Clinic FoundationResidency, Internal Medicine, 1995 - 1998
OtherClass of 1984
Cairo University School of MedicineClass of 1984
Certifications & Licensure
FL State Medical License 2008 - 2025
OH State Medical License 1998 - 2010
IA State Medical License 1997 - 1999- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Lenalidomide, Docetaxel, and Carboplatin in Treating Patients With Advanced Solid Tumors Start of enrollment: 2004 Aug 01
- Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Start of enrollment: 2009 Nov 01
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- 1805 citationsOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLCScott J. Antonia, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami
The New England Journal of Medicine. 2018-09-25 - 28 citationsEfficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non–Small-Cell Lung C...Heather A. Wakelee, Zanete Zvirbule, Filippo de Braud, C. Daniel Kingsley, Tarek Mekhail
Clinical Lung Cancer. 2017-01-01 - 80 citationsBlood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.Edward S Kim, Vamsidhar Velcheti, Tarek Mekhail, Cindy Yun, Sarah M Shagan
Nature Medicine. 2022-05-01
Journal Articles
- Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLCDavid R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine
Press Mentions
FHCI to Host Oncology UpdateJune 26th, 2011
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
